Infratil Limited (ASX:IFT)
Australia · Delayed Price · Currency is AUD | Market Cap | 12.36B +34.2% |
| Revenue (ttm) | 3.83B +36.6% |
| Net Income | 496.84M |
| EPS | 0.49 |
| Shares Out | n/a |
| PE Ratio | 24.88 |
| Forward PE | 61.95 |
| Dividend | 0.19 (1.55%) |
| Ex-Dividend Date | Nov 26, 2025 |
| Volume | 263,936 |
| Average Volume | 375,969 |
| Open | 12.40 |
| Previous Close | 12.44 |
| Day's Range | 12.31 - 12.49 |
| 52-Week Range | 8.78 - 12.56 |
| Beta | 0.03 |
| RSI | 87.89 |
| Earnings Date | May 26, 2026 |
About Infratil
Infratil Limited is an infrastructure investment firm specializing in digital Infrastructure, renewables, and social infrastructure. They prefer to invest in renewable electricity, data centers, telecommunications networks healthcare, and airports. It invests around the world. The company was incorporated in 1994 and is based in Wellington, New Zealand. [Read more]
News
Infratil powers to new high with CDC deal, lifting NZ stocks with it – Market close
CDC has announced the largest datacentre deal in Australia’s history, with a US customer.
Infratil Transcript: Status update
A record-breaking contract with a U.S. hyperscaler boosts contracted capacity above 1 GW and secures nearly 100% investment-grade counterparties. EBITDAF is set to exceed AUD 1 billion in FY2028, with funding fully supported by existing debt and no new equity required. Sustainability, technological leadership, and a robust pipeline position the business for continued outsized growth.
Infratil’s CDC wins biggest data centre contract in Australia’s history
CDC forecasts ebitdaf of about A$2b a year once the new capacity is fully used.
Infratil reinstated with a Buy at Jefferies
Jefferies reinstated coverage of Infratil (IFUUF) with a Buy rating and A$12.10 price target The firm, which adjusted forecasts to account for asset divestments, values shares based on a sum-of-the-pa...
Infratil Earnings Call Transcript: H1 2026
Half-year results show 7% EBITDA growth, led by CDC and Longroad, with strong contract wins and asset divestments advancing strategic goals. Updated guidance reflects CDC at lower end and Longroad raised, while financial flexibility and sustainability credentials remain robust.
Infratil Transcript: AGM 2025
The meeting reviewed strong financial performance, strategic asset moves, and board succession plans. Shareholders discussed management fees, portfolio concentration, and sustainability, with all resolutions—including director re-elections and fee payment options—passed by vote.
Infratil Earnings Call Transcript: H2 2025
Proportionate EBITDA reached NZD 986 million, with portfolio value up 29% and strong growth in digital, renewables, and healthcare segments. FY2026 guidance targets up to NZD 1.05 billion EBITDA, with CDC and Longroad positioned for multi-year expansion.
Infratil resumed with a Neutral at Goldman Sachs
Goldman Sachs resumed coverage of Infratil (IFUUF) with a Neutral rating and NZ$11.50 price target The firm says execution risks and policy uncertainties remain headwinds for the company. Published fi...
Infratil Earnings Call Transcript: H1 2025
Strong half-year results driven by CDC, 1NZ, and Wellington Airport, with EBITDA up 7% year-over-year and robust CapEx supporting future growth. Guidance narrowed, with CDC and Long Road facing timing and policy uncertainties, but overall outlook remains positive.
Infratil Transcript: AGM 2024
The meeting highlighted a strong 30-year performance, robust FY24 results, and major investments in digital and renewables. Key initiatives include CDC data center expansion, One NZ's new offerings, and ongoing sustainability efforts. Shareholder engagement and governance remain priorities.
Infratil Earnings Call Transcript: H2 2024
Infratil Earnings Call Transcript: H1 2024
Infratil Transcript: AGM 2023
Infratil initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Niraj Shah initiated coverage of Infratil with a Neutral rating and NZ$10.40 price target. The analyst believes the company’s growth opportunities and risks are largely priced in...